@techreport{oai:kindai.repo.nii.ac.jp:00021477,
 author = {高間, 勇一 and 田附, 裕子 and 奥山, 宏臣 and 児玉, 匡},
 month = {},
 note = {https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-16K10089/, 研究成果の概要（和文）：本研究では，壊死性腸炎（NEC）モデルにおいて組み換えヒト可溶性トロンボモジュリン（rTM）の効果を検討した．NECモデルは，高浸透圧の経管強制栄養，lipopolysaccharideの胃内投与，低酸素ストレスにより作成した．治療群では，rTMを皮下投与した．組織学的にNEC様の腸管傷害は，NEC群（73.5％）にくらべ，治療群（36％）で有意に少なかった．組織のTNF-α，IL-6，HMGB1は，NEC群では有意に上昇していたが，rTM治療群では,減少していた．本研究で，rTMによる治療は，NECの重症度を軽減させることが示された．rTMはNEC治療の選択肢の一つになる可能性が示唆された．研究成果の概要（英文）：NEC remains the leading cause of death in preterm infants. The aim of this study was to evaluate the effect of Recombinant human soluble thrombomodulin (rTM) in a NEC model. NEC was induced by enteral feeding with hyperosmolar formula, gavage administration of lipopolysaccharide and asphyxia stress. In the treatment group, rTM was administered subcutaneously twice . The ileum was harvested for a histological evaluation and the measurement of the mRNA and protein expression. The rate of NEC-like intestinal injury in the treatment group (36%) was significantly lower than in the NEC group (73.5%). Tissue levels of TNF-alpha, IL-6 and HMGB1 were significantly elevated in the NEC group, whereas those in the treatment group were decreased to similar values as in the control group. Our experimental study showed that rTM is able to reduce the severity and incidence of NEC. It may be an alternative option for the treatment of NEC., 研究種目：基盤研究(C);  研究期間：2016～2019;   課題番号：16K10089;   研究分野：小児外科;   科研費の分科・細目：, application/pdf},
 title = {壊死性腸炎（NEC）に対する補体系制御による治療法の開発},
 year = {2020},
 yomi = {タカマ, ユウイチ and タズケ, ユウコ and オクヤマ, ヒロオミ and コダマ, タスク}
}